精(jing)華(hua)制(zhi)(zhi)(zhi)(zhi)藥(yao)集(ji)團股(gu)份有限公司(si)是(shi)由南(nan)(nan)通產控(kong)集(ji)團控(kong)股(gu)、國資(zi)監管的地方國有控(kong)股(gu)企業,由原南(nan)(nan)通中誠(cheng)制(zhi)(zhi)(zhi)(zhi)藥(yao)有限公司(si)(南(nan)(nan)通中藥(yao)廠(chang))變更(geng)、重組南(nan)(nan)通制(zhi)(zhi)(zhi)(zhi)藥(yao)總廠(chang)(南(nan)(nan)通制(zhi)(zhi)(zhi)(zhi)藥(yao)廠(chang)、南(nan)(nan)通制(zhi)(zhi)(zhi)(zhi)藥(yao)二廠(chang))優質資(zi)源,并(bing)吸收(shou)民營資(zi)本(ben)南(nan)(nan)通綜藝(yi)投(tou)資(zi)有限公司(si)以(yi)及自然(ran)人投(tou)資(zi)設立。2010年2月(yue)在深交所(suo)中小板(ban)掛(gua)牌上市,股(gu)票簡稱(cheng):精(jing)華(hua)制(zhi)(zhi)(zhi)(zhi)藥(yao),證券代號:002349。
公司已有(you)(you)60多年的(de)制(zhi)(zhi)(zhi)藥(yao)(yao)(yao)歷史(shi),是一家綜(zong)合性的(de)現代化(hua)GMP制(zhi)(zhi)(zhi)藥(yao)(yao)(yao)有(you)(you)限公司。目前擁有(you)(you)7個(ge)子公司,是一家集中(zhong)(zhong)藥(yao)(yao)(yao)制(zhi)(zhi)(zhi)劑、中(zhong)(zhong)藥(yao)(yao)(yao)飲片(pian)、西藥(yao)(yao)(yao)制(zhi)(zhi)(zhi)劑、醫(yi)藥(yao)(yao)(yao)中(zhong)(zhong)間(jian)體、化(hua)學原(yuan)料藥(yao)(yao)(yao)、生物制(zhi)(zhi)(zhi)藥(yao)(yao)(yao)、保(bao)健品(pin)(pin)等(deng)生產、銷售和研(yan)發的(de)綜(zong)合型(xing)制(zhi)(zhi)(zhi)藥(yao)(yao)(yao)企業集團。公司有(you)(you)中(zhong)(zhong)西藥(yao)(yao)(yao)品(pin)(pin)種(zhong)(zhong)(zhong)200余種(zhong)(zhong)(zhong),中(zhong)(zhong)藥(yao)(yao)(yao)產品(pin)(pin)主要有(you)(you)享譽(yu)海內外(wai)的(de)經典名(ming)藥(yao)(yao)(yao)“五朵(duo)金花”王(wang)氏保(bao)赤(chi)丸(wan)、季(ji)德勝(sheng)蛇藥(yao)(yao)(yao)片(pian)、正柴(chai)胡(hu)飲顆(ke)粒、大柴(chai)胡(hu)顆(ke)粒、金蕎麥膠(jiao)囊,以及(ji)固本咳喘片(pian)、暈(yun)可平(ping)糖(tang)漿(jiang)、精血補片(pian)等(deng),這些中(zhong)(zhong)藥(yao)(yao)(yao)品(pin)(pin)種(zhong)(zhong)(zhong)都有(you)(you)著廣泛(fan)的(de)歷史(shi)背景(jing)及(ji)深厚的(de)文(wen)化(hua)底蘊,其中(zhong)(zhong)季(ji)德勝(sheng)蛇藥(yao)(yao)(yao)片(pian)、王(wang)氏保(bao)赤(chi)丸(wan)制(zhi)(zhi)(zhi)作(zuo)技(ji)藝均被列入國家非(fei)物質(zhi)文(wen)化(hua)遺產。原(yuan)料藥(yao)(yao)(yao)產品(pin)(pin)主要有(you)(you)苯巴(ba)比(bi)妥、撲米酮、氟尿(niao)嘧(mi)啶(ding)、保(bao)泰松、氟胞嘧(mi)啶(ding)、吡羅昔康、替(ti)諾昔康、丙硫氧嘧(mi)啶(ding)、非(fei)那(nei)西丁、雙嘧(mi)達莫以及(ji)其它(ta)醫(yi)藥(yao)(yao)(yao)中(zhong)(zhong)間(jian)體等(deng)。其中(zhong)(zhong)已有(you)(you)10個(ge)品(pin)(pin)種(zhong)(zhong)(zhong)通(tong)(tong)過(guo)國家GMP認(ren)(ren)證(zheng),5個(ge)品(pin)(pin)種(zhong)(zhong)(zhong)通(tong)(tong)過(guo)歐(ou)盟CEP認(ren)(ren)證(zheng),2個(ge)品(pin)(pin)種(zhong)(zhong)(zhong)通(tong)(tong)過(guo)澳大利(li)亞GMP認(ren)(ren)證(zheng),3個(ge)品(pin)(pin)種(zhong)(zhong)(zhong)通(tong)(tong)過(guo)墨西哥官方認(ren)(ren)證(zheng),4個(ge)品(pin)(pin)種(zhong)(zhong)(zhong)獲(huo)得美國DMF注冊文(wen)件 ,1個(ge)品(pin)(pin)種(zhong)(zhong)(zhong)獲(huo)得美國VMF注冊文(wen)件,并已通(tong)(tong)過(guo)美國FDA現場(chang)核查(cha)。
精(jing)華制(zhi)藥(yao)將會以(yi)“成為(wei)以(yi)傳世中藥(yao)為(wei)核心特(te)色的(de)(de)全國現(xian)(xian)代醫藥(yao)企業(ye)(ye)”為(wei)戰略(lve)目標,深入貫(guan)徹(che)《關于促進中醫藥(yao)傳承創新發展的(de)(de)意見》精(jing)神(shen),聚焦(jiao)“五朵金(jin)花”傳世中藥(yao)主業(ye)(ye)為(wei)主,特(te)色化學(xue)原(yuan)料藥(yao)及化學(xue)制(zhi)劑為(wei)輔的(de)(de)“雙輪驅動”的(de)(de)發展戰略(lve),依托品牌力和(he)渠道力,致力于成為(wei)以(yi)傳世中藥(yao)為(wei)核心特(te)色的(de)(de)全國現(xian)(xian)代醫藥(yao)企業(ye)(ye)。